Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609020 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22213795 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2603292 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12609019 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14213446 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2603280 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4102035 | 0.87 | CHRNB2 (0.48) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28814955 | 0.86 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8034151 | 0.86 | CHRNB2 (0.50) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18729770 | 0.85 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| US-20220175788-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2022-06-09 | — | — | US | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | THE UNIVERSITY OF EDINBURGH (GB) | 2011-01-20 | — | — | US | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010033941-A1 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | CHRNB2 3891/4885CHRNA7 2165/4885CHRNA4 4407/4885 |
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CHRNB2 1125/4885CHRNA7 1599/4885CHRNA4 1993/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | CHRNB2 1151/4885CHRNA7 1015/4885CHRNA4 992/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | CHRNB2 4792/4885CHRNA7 4845/4885CHRNA4 4877/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | CHRNB2 2211/4885CHRNA7 1663/4885CHRNA4 1692/4885 |
| US-20220175788-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | CDK6, IL6, CDK4 | CHRNB2 3916/4885CHRNA7 3159/4885CHRNA4 2578/4885 |
| US-20110015178-A1 | Amido-Thiophene Compounds and Their Use | HSD11B1, HSD11B2, HSD17B1 | CHRNB2 1734/4885CHRNA7 2734/4885CHRNA4 2831/4885 |
| US-20110166122-A1 | SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | NTRK1, NTRK3, NTRK2 | CHRNB2 796/4885CHRNA7 855/4885CHRNA4 806/4885 |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | CHRNB2 3916/4885CHRNA7 3159/4885CHRNA4 2578/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | CHRNB2 856/4885CHRNA7 337/4885CHRNA4 676/4885 |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | CHRNB2 11/4885CHRNA7 14/4885CHRNA4 15/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CHRNB2 1521/4885CHRNA7 1061/4885CHRNA4 1125/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | CHRNB2 1944/4885CHRNA7 3035/4885CHRNA4 3198/4885 |
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | CHRNB2 2827/4885CHRNA7 2062/4885CHRNA4 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.